For Industry

Generic Drug User Fee Amendments of 2012

Latest News:

On October 28, 2016, 1 PM, ET, CDER will host a LIVE webinar titled: "Overview of GDUFA II and Implementation of GDUFA II User Fees".

This webinar will provide a brief overview of changes to the user fee structure under GDUFA II and what it means for regulated industry. We will discuss those changes to the user fee structure under GDUFA II and describe how CDER and Industry can best prepare for GDUFA II go-live on October 1, 2017.

Featured Speakers include:
Donal Parks, Director, Division of User Fee Management and Budget Formulation
Gisa Perez, Branch Chief, Generics, Division of User Fee Management and Budget Formulation

This webinar has been pre-approved by RAPS as eligible for up to 1 credit towards a participant's RAC recertification upon full completion.

Register Now!disclaimer icon

GDUFA, an historic first: Providing user fees for FDA to ensure timely review of applications for generic drugs

 

The Generic Drug User Fee Amendments of 2012 (GDUFA) is designed to speed access to safe and effective generic drugs to the public and reduce costs to industry. The law requires industry to pay user fees to supplement the costs of reviewing generic drug applications and inspecting facilities. Additional resources will enable the Agency to reduce a current backlog of pending applications, cut the average time required to review generic drug applications for safety, and increase risk-based inspections.

GDUFA is designed to build on the success of the Prescription Drug User Fee Act (PDUFA).  Over the past 20 years, PDUFA has ensured a more predictable, consistent, and streamlined premarket program for industry and helped speed access to new, safe and effective prescription drugs for patients.  GDUFA will also enhance global supply chain safety by requiring that generic drug facilities and sites around the world self-identify.

The current legislative authority for GDUFA expires at the end of September 2017. At that time, new legislation will be required for FDA to continue to collect generic drug user fees for future fiscal years. More information on recent developments related to the reauthorization of GDUFA is available at the GDUFA Reauthorization Website.

FY17 GDUFA Fees Table

ANDA$70,480
PAS$35,240
DMF$51,140
FacilityDomestic API$44,234
Foreign API$59,234
Domestic FDF$258,646
Foreign FDF$273,646
BacklogN/A

 

GDUFA Legislation

On July 9, 2012, the President signed into law the Food and Drug Administration Safety and Innovation Act (FDASIA). This new law includes the Generic Drug User Fee Amendments of 2012 (GDUFA) which is designed to speed access to safe and effective generic drugs to the public. GDUFA authorizes the Food and Drug Administration (FDA) to collect fees from drug companies that submit marketing applications for certain generic human drug applications, certain drug master files, and certain facilities.

Page Last Updated: 12/02/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English